Tenofovir DF + Emtricitabine + Elvitegravir + Cobicistat bulk supplier for pharma manufacturers

Tenofovir Df + Emtricitabine + Elvitegravir + Cobicistat Suppliers & Bulk Manufacturers

Available Forms: Oral tablet (film-coated)

Available Strengths: Elvitegravir – 150 mg + Cobicistat – 150 mg + Emtricitabine – 200 mg + TDF – 300 mg

Reference Brands: Stribild (US & EU)

Stribild is a once-daily HIV-1 treatment combining TDF, Emtricitabine, Elvitegravir, and Cobicistat in one tablet. FDA and EMA approved, it provides effective viral suppression and improved adherence. Must be taken with food.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Tenofovir Disoproxil Fumarate (TDF) + Emtricitabine + Elvitegravir + Cobicistat, marketed as Stribild, is a complete, once-daily, single-tablet regimen for the treatment of HIV-1 infection in treatment-naïve adults and adolescents. This fixed-dose combination includes an integrase inhibitor (Elvitegravir), two NRTIs (TDF and Emtricitabine), and a pharmacokinetic booster (Cobicistat). Approved by the US FDA and EMA, Stribild offers strong viral suppression and improved patient adherence by reducing pill burden. It must be taken with food to ensure optimal absorption. Stribild is widely used in global HIV programs, though newer TAF-based regimens like Genvoya offer improved renal and bone safety.

Tenofovir Df + Emtricitabine + Elvitegravir + Cobicistat — third party manufacturing & bulk supply

Tenofovir Df + Emtricitabine + Elvitegravir + Cobicistat is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Tenofovir Df + Emtricitabine + Elvitegravir + Cobicistat is supplied as Oral tablet (film-coated) — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Tenofovir Df + Emtricitabine + Elvitegravir + Cobicistat listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Tenofovir Df + Emtricitabine + Elvitegra... →

Back to Listing

Frequently Asked Questions

Tenofovir DF, Emtricitabine, Elvitegravir, and Cobicistat are combined to treat human immunodeficiency virus (HIV-1) infection. This fixed-dose combination helps reduce the amount of HIV in the body, maintains immune function, and lowers the risk of developing HIV-related complications.

This combination contains four active antiretroviral ingredients: Tenofovir Disoproxil Fumarate (a nucleotide reverse transcriptase inhibitor), Emtricitabine (a nucleoside reverse transcriptase inhibitor), Elvitegravir (an integrase strand transfer inhibitor), and Cobicistat (a pharmacokinetic enhancer that increases Elvitegravir levels by inhibiting CYP3A enzymes).

The main trade name for this fixed-dose combination is Stribild.

Stribild is manufactured by Gilead Sciences, Inc.

The generic name is Tenofovir Disoproxil Fumarate, Emtricitabine, Elvitegravir, and Cobicistat.

The brand name is Stribild.

Stribild and its generic versions are manufactured in the United States by Gilead Sciences and by WHO-GMP-approved facilities in India and other countries for global distribution.